This pattern of correlation with SIRT2 gene expression is also seen in general T cell markers (eg, CD3D, CD3E, CD2) and in some other immune cell populations (eg, most naive T cell markers, effector memory T cells, effector T cells, and natural killer cells), such as LEF1 which has been shown to predict variations in response to treatment in AML. This evidence concerns the gene SIRT2 and acute myeloid leukemia.